W hen GlaxoSmithKline spins off its enormous division selling drugstore staples like Advil and Tums next month, it will represent more than just the latest shuffling of assets among corporate giants.
It will mark what is effectively the end of GlaxoSmithKline, diversified pharma conglomerate, and the birth of GSK (ticker: GSK), a rebranded pure-play biopharma.
The…
Source: https://www.barrons.com/articles/the-days-of-big-pharma-are-over-big-biotech-is-on-its-way-51655449202?siteid=yhoof2&yptr=yahoo